Relevant thoughts on development of traditional Chinese medicine industry in new era.
10.19540/j.cnki.cjcmm.20220527.501
- Author:
Ju HUANG
1
;
Geng LI
2
;
Xiao-Xiao ZHANG
3
;
Yong MA
4
;
Zhi-Lai ZHAN
5
;
Wei-An YUAN
6
;
Li-Ping QU
7
;
Shi-Yao HUANG
1
;
Bo LI
8
;
Bo-Hua YAN
1
;
Wen-Yuan LI
1
;
Li LIU
9
;
Zhi-Lei WANG
1
;
Yi FENG
10
;
Lei ZHANG
10
;
Jian-Yuan TANG
1
Author Information
1. Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610032, China.
2. Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing 100193, China.
3. China Association of Chinese Medicine Beijing 100029, China.
4. School of Chinese Medicine·School of Integrated Chinese and Western Medicine,Nanjing University of Chinese Medicine Nanjing 210023, China.
5. National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China.
6. Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai 201203, China.
7. State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine Chengdu 610032, China.
8. Beijing Hospital of Traditional Chinese Medicine,Capital Medical University/Beijing Institute of Chinese Medicine/Beijing Evidence-based Chinese Medicine Center Beijing 100010, China.
9. Shanghai Pharmaceuticals Holding Co., Ltd. Shanghai 200020, China.
10. Shanghai University of Traditional Chinese Medicine Shanghai 201203, China.
- Publication Type:Journal Article
- Keywords:
policy analysis;
strategic thinking;
the new era;
traditional Chinese medicine industry
- MeSH:
China;
Drugs, Chinese Herbal;
Humans;
Industry;
Medicine, Chinese Traditional;
Policy
- From:
China Journal of Chinese Materia Medica
2022;47(17):4799-4813
- CountryChina
- Language:Chinese
-
Abstract:
Since the 18th National Congress of the Communist Party of China(CPC), the CPC and the government have highligh-ted the development of traditional Chinese Medicine(TCM) and issued a series of policies, such as the Plan for Protection and Deve-lopment of Chinese Medicinal Materials(2015-2020) forwarded by the General Office of the State Council in 2015, the Plan for Healthy Development of Traditional Chinese Medicine(2015-2020) released by the General Office of the State Council in the same year, the Healthy China 2030 Plan published by the CPC Central Committee and the State Council in 2016, the Law of the People's Republic of China on Traditional Chinese Medicine which took effect on July 2017, On the Preservation and Innovative Development of Traditional Chinese Medicine promulgated by CPC Central Committee and the State Council in 2019, and Plan for the Development of Traditional Chinese Medicine during the 14th Five-Year Plan Period of China released by the General Office of the State Council in March 2022, to promote the development of the TCM industry, which have brought historical opportunities to the TCM industry. However, TCM industry faces various challenges in the development. In terms of drug development in TCM, the current studies mainly focused on the chemical research and technical requests, which neglected TCM characteristics and cased in conformity between new drug transformation of TCM and clinical practice. Therefore, a more considerable and profound authoritative guideline is needed, and innovative thought and research are necessary for academics and the industry. Through the investigation of the development TCM industry in recent years, this study summarized the policies on and trends of Chinese medicinal materials, new drug development in TCM, catalogue of national basic drugs, and national basic health insurance, and proposed suggestions for further development of TCM industry.
